Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Perimetric testing patterns focusing on the central visual field region can be more sensitive to glaucomatous progression than more peripheral patterns
Author Affiliations & Notes
  • Yujia Wang
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Iván Marin-Franch
    Computation Optometry, Ivan Marin-Franch, Atarfe, Granada, Spain
  • Carlos Gustavo De Moraes
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Ari Leshno
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
    Sheba Medical Center, Tel Hashomer, Israel
  • Aakriti Garg Shukla
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Jeffrey M Liebmann
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • George A. Cioffi
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Donald Hood
    Psychology, Columbia University, New York, New York, United States
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Emmanouil Tsamis
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Footnotes
    Commercial Relationships   Yujia Wang None; Iván Marin-Franch Envision Health Technologies Inc. , Code E (Employment); Carlos Moraes Carl Zeiss, Novartis, Perfuse Therapeutics, Thea Pharma, Galimedix, Code C (Consultant/Contractor), Ora Clinical, Code E (Employment), Topcon, Carl Zeiss, RPB, Code R (Recipient); Ari Leshno None; Aakriti Garg Shukla Alcon Inc., Allergan Inc., Thea Inc., Code C (Consultant/Contractor), Thea Inc. , Code R (Recipient); Jeffrey Liebmann AdvanceSight, Alcon Inc., Allergan Inc., Carl Zeiss Meditech, Genentech Inc., Johnson and Johnson Inc., ONL Therapeutics Inc., Thea Inc. , Code C (Consultant/Contractor); George A. Cioffi None; Donald Hood Novartis, Heidelberg Eng., Topcon Inc., Code F (Financial Support), Heidelberg Eng., Topcon Inc. , Code R (Recipient); Emmanouil Tsamis Envision Health Technologies Inc. , Code C (Consultant/Contractor), Topcon Inc.,, Code F (Financial Support)
  • Footnotes
    Support  Emmanouil Tsamis: K99 EY032182. Aakriti G. Shukla: Columbia University Clinical and Translational Science Award NIH UL1TR001873. George A. Cioffi: Unrestricted Grant from Research to Prevent Blindness.
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4800. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yujia Wang, Iván Marin-Franch, Carlos Gustavo De Moraes, Ari Leshno, Aakriti Garg Shukla, Jeffrey M Liebmann, George A. Cioffi, Donald Hood, Emmanouil Tsamis; Perimetric testing patterns focusing on the central visual field region can be more sensitive to glaucomatous progression than more peripheral patterns. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4800.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the sensitivity to detect functional progression based upon the 10-2 and 24-2 visual field (VF) testing patterns using permutation of pointwise linear regression (PoPLR) analysis.

Methods : A series of 24-2 and 10-2 VF tests were obtained from 103 eyes/patients with, or suspected, glaucoma, as part of the observational Macular Progression Study (MAPS). The median number of VF tests per series was 10 (range: 6-14) with a mean follow up of 4.3 years (range: 1-7 years). Total deviation values from all 24-2 and 10-2 locations were obtained (Fig. 1). Progression was assessed using PoPLR to construct a 1-tail significance test for the alternative hypothesis that there is loss occurring over time.[1] In addition, to the 24-2 and 10-2 VF testing patterns, we also evaluated: 1) the central 12 locations of the 24-2 alone (24-2C12) (Fig. 1B, 12 locations encircled with red); and, 2) a hybrid pattern that involved the 10-2 and the 24-2 excluding the central 12 locations (24-2Per+10-2). Positive rates (PR) and false positive rates (FPR) were obtained for detection of progression. For comparison purposes, PR was also obtained for simple linear regression of the mean deviation (MD) of the 24-2 and 10-2 test patterns.

Results : At a 5% significance level (Fig. 2), point-wise analyses on the 10-2 pattern had the highest PR at 28%, while the 24-2 VF test pattern had the lowest PR (23%). The 24-2C12 and the 24-2Per+10-2 patterns, which contain information from the central field region, also outperformed the 24-2; PRs: 26% and 27%, respectively. Analyses based upon point-by-point measures outperformed those of global indices of the 24-2 (PR: 24%) but not of the 10-2 (PR: 28%).

Conclusions : A pointwise approach for detecting progression of glaucomatous damage based upon functional measures had greater PR than global indices of the 24-2. Sensitivity can improve by obtaining more measures (i.e., testing more locations) in the central region of the visual field. However, even the 10-2 VF with the highest reported PR should not be solely relied upon for detection of progressive damage, as structural measurements or joint (structure-function) analyses can achieve higher PRs.[2]
1. O’Leary et al., IOVS, 2012; 2. Abu et al. PLoS ONE, 2022

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×